



Charles River Promotes Foster Jordan to Corporate Senior Vice President

November 19, 2008

WILMINGTON, Mass., Nov 19, 2008 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the promotion of Foster Jordan to Corporate Senior Vice President, Endotoxin & Microbial Detection Products.

"With Foster's direction our in vitro solutions are market leaders and pillars in the Company's success. His ability to anticipate both industry and customer demands will help drive the continued growth and profitability of our in vitro business moving forward," said James C. Foster, Chairman, President, and Chief Executive Officer of Charles River.

Mr. Jordan joined Charles River in 1994 following the acquisition of Endosafe. He became Executive Director, In Vitro Detection Systems in 2001 and a Corporate Vice President in 2006. Mr. Jordan was instrumental in the development of the Company's FDA-licensed in vitro endotoxin detection test kits. Under his leadership, Charles River's in vitro business continues to evolve and meet the increased market demand for rapid, real-time endotoxin testing. The innovative solutions support the FDA's Process Analytical Technology (PAT) initiative.

"The increased customer demand, coupled with the PAT initiative, makes this a very exciting time for in vitro endotoxin detection tests," said Foster Jordan, Corporate Senior Vice President, Endotoxin & Microbial Detection Products. "More and more customers are realizing rapid FDA approved endotoxin detection is the future and I look forward to helping these organizations implement best practices with Charles River solutions."

About Charles River

Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our more than 9,000 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Caution Concerning Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements include statements regarding expected growth and profitability of Charles River's in vitro business and anticipated increased demand for rapid, real time endotoxin testing. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 20, 2008, as well as other filings we make with the Securities and Exchange Commission. Charles River assumes no obligation and expressly disclaims any duty to update information contained in this release except as required by law.

SOURCE: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

Media Contact:

Amy Cianciaruso, 781-222-6168

amy.cianciaruso@crl.com

or

Investor Contact:

Susan E. Hardy, 781-222-6190

susan.hardy@crl.com